[go: up one dir, main page]

BRPI0506694A - análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação - Google Patents

análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação

Info

Publication number
BRPI0506694A
BRPI0506694A BRPI0506694-8A BRPI0506694A BRPI0506694A BR PI0506694 A BRPI0506694 A BR PI0506694A BR PI0506694 A BRPI0506694 A BR PI0506694A BR PI0506694 A BRPI0506694 A BR PI0506694A
Authority
BR
Brazil
Prior art keywords
analogs
peptide
long
acting glucagon
glucagon
Prior art date
Application number
BRPI0506694-8A
Other languages
English (en)
Inventor
Krishna Peri
Daniel Abran
Abdelkrim Habi
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BRPI0506694A publication Critical patent/BRPI0506694A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANáLOGOS DE PEPTìDEO-1 SEMELHANTE AO GLUCAGON COM LONGA DURAçãO DE AçãO. Novos análogos de glp-1 tendo potência biológica aperfeiçoada, bem como atividade farmacológica estendida são descritos aqui. mais especificamente, a presente invenção se refere a análogos de glp-1 (28 ou 29 aa de comprimento) compreendendo de aminoácidos em um ou mais das sequintes posições: 8, 20, 27, 30 e 33.
BRPI0506694-8A 2004-01-08 2005-01-07 análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação BRPI0506694A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53468204P 2004-01-08 2004-01-08
US57007304P 2004-05-12 2004-05-12
PCT/CA2005/000022 WO2005066207A1 (en) 2004-01-08 2005-01-07 Glucagon-like peptide-1 analogs with long duration of action

Publications (1)

Publication Number Publication Date
BRPI0506694A true BRPI0506694A (pt) 2007-05-02

Family

ID=34753021

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506694-8A BRPI0506694A (pt) 2004-01-08 2005-01-07 análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação

Country Status (7)

Country Link
US (1) US7538185B2 (pt)
EP (1) EP1709071A4 (pt)
JP (1) JP2007537149A (pt)
AU (1) AU2005203925A1 (pt)
BR (1) BRPI0506694A (pt)
CA (1) CA2552526A1 (pt)
WO (1) WO2005066207A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471811B1 (en) * 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
EP2004213A1 (en) * 2006-04-03 2008-12-24 Novo Nordisk A/S Glp-1 peptide agonists
CN101454342A (zh) 2006-05-26 2009-06-10 安米林药品公司 用于治疗充血性心力衰竭的组合物及方法
CA2655923A1 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof
CA2707132A1 (en) * 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
EP2384338A4 (en) * 2008-12-29 2013-01-16 Panacea Biotec Ltd GLP-1 ANALOGS AND THEIR APPLICATIONS
EP2571897B1 (en) * 2010-05-17 2014-11-05 Betta Pharmaceuticals Co., Ltd. Novel glucagon like peptide analogs, composition, and method of use
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US20190290772A1 (en) * 2016-06-02 2019-09-26 Indiana University Research And Technology Corporation Glucagon-like peptide-1-t3 conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DK0512042T3 (da) * 1990-01-24 1998-05-11 Douglas I Buckley GLP-1-analoger anvendelige ved diabetesbehandling
PL176007B1 (pl) 1992-06-15 1999-03-31 Scios Inc Nowe pochodne polipeptydu GLP-1
DE69737479D1 (de) 1996-08-30 2007-04-26 Novo Nordisk As Glp-1 derivate
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
AU2610599A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
CN101108878B (zh) * 1998-12-07 2012-08-29 研究及应用科学协会股份有限公司 胰高血糖素样肽-1的类似物
EP1359159A3 (en) 1998-12-07 2004-07-21 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of GLP-1
JP3702181B2 (ja) 1998-12-07 2005-10-05 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
DK1695983T3 (da) 2000-06-16 2009-05-18 Lilly Co Eli Glucagon-lignende peptid-1 analoger
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
WO2003018516A2 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
JP4282485B2 (ja) 2002-01-08 2009-06-24 イーライ リリー アンド カンパニー 伸長グルカゴン様ペプチド−１アナログ
CA2500021A1 (en) * 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency

Also Published As

Publication number Publication date
EP1709071A1 (en) 2006-10-11
US7538185B2 (en) 2009-05-26
WO2005066207A1 (en) 2005-07-21
WO2005066207A8 (en) 2006-02-02
JP2007537149A (ja) 2007-12-20
AU2005203925A1 (en) 2005-07-21
US20060014685A1 (en) 2006-01-19
CA2552526A1 (en) 2005-07-21
EP1709071A4 (en) 2007-05-30

Similar Documents

Publication Publication Date Title
PE20011363A1 (es) Analogos del peptido-1 semejante a glucagon
NZ514610A (en) Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
NZ517012A (en) Peptides that lower blood glucose levels
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
AR109274A2 (es) Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento
AR046877A1 (es) Muteinas del factor de crecimiento de fibroblastos 21
NZ603445A (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
SE9801992D0 (sv) New 3-aryl-2-hydroxypropionic acid derivative I
AR061203A1 (es) Moduladores del receptor glp-1 modificados en la terminal n
DE602006020123D1 (de) Glucagon-like-peptide-2- (glp-2-) analoga
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
BRPI0413276B8 (pt) derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
BRPI0408331B8 (pt) conjugado de proteína, processo para preparação do dito conjugado de proteína, composição farmacêutica e processo para prolongar a meia vida útil in vivo de um polipeptídeo fisiologicamente ativo
MX2008004734A (es) Composicion rica en leucina.
ATE466028T1 (de) N-terminal veränderte glp-1 abkömmlinge
ATE517119T1 (de) Einzelketteninsulin
FI2571517T4 (fi) Insuliinien pitkävaikutteisia formulaatioita
MX2007012102A (es) Control superior de glucosa en la sangre en tratamiento de diabetes.
BRPI0506694A (pt) análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
ES2061797T3 (es) Mini-proinsulina, su preparacion y empleo.
UY29088A1 (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos
AR079876A1 (es) Gonadotrofina corionica humana recombinante con alto contenido de acido sialico y uso farmaceutico de la misma
ATE267601T1 (de) Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2205 DE 09/04/2013.